Exelixis Inc. Aktie
23,12 €
Deine Einschätzung
Exelixis Inc. Aktie
Was spricht für und gegen Exelixis Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Exelixis Inc. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Exelixis Inc. | 1,64 % | -3,26 % | 11,69 % | 16,77 % | 5,67 % | 44,64 % | 28,26 % |
Ironwood Pharmaceuticals | -5,38 % | 7,65 % | -33,02 % | -50,06 % | -58,63 % | -61,98 % | -45,35 % |
Arrowhead Pharmaceuticals Inc. | 0,73 % | 7,43 % | -16,55 % | -15,98 % | -21,41 % | -58,17 % | -20,18 % |
Novocure Ltd | 0,65 % | -0,77 % | -6,88 % | -41,61 % | 12,82 % | -86,01 % | -80,60 % |
Kommentare
News
![3 Stocks to Buy for a Soft Landing, If There Is One: https://www.marketbeat.com/logos/articles/med_20240815092649_3-stocks-to-buy-for-a-soft-landing-if-there-is-one.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNmo1YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c66f1006d9160283786cdffff5162f23b744f556/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240815092649_3-stocks-to-buy-for-a-soft-landing-if-there-is-one.jpg?locale=de)
3 Stocks to Buy for a Soft Landing, If There Is One
Recent economic data is reigniting talk about a soft landing for the economy. That means that the Federal Reserve’s monetary policy regarding interest rates is neither too restrictive nor too
![Exelixis (EXEL) Q2 2024 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=de)
Exelixis (EXEL) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
Exelixis (NASDAQ: EXEL)Q2 2024 Earnings CallAug 06, 2024, 5:00 p.m. ET
Operator
Source Fool.com
![Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?: https://g.foolcdn.com/editorial/images/776121/physician-talking-to-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMWFXYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--99d8196e52f82ce755c490f9294c8fe48441668b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physician-talking-to-patient.jpg?locale=de)
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
Many billionaire investors are going all in on artificial intelligence (AI). That's understandable. AI is quickly being integrated into businesses' day-to-day operations. The leaders in the field